ONODERA GT Pharma, Inc.
Development of gene therapy
Using adeno-associated virus (AAV) as a vector to carry therapeutic genes, we are developing
gene therapy for intractable diseases for which no effective treatment has been available so far.
We are planning to apply for conditional and time-limited market approval for amyotrophic
lateral sclerosis (ALS) and have already started clinical trials for Parkinson's disease, and Glut1
deficiency. We would like to implement the therapy in a practical clinical setting as soon as possible.
Life Innovation Center (LIC)
Regenerative Medicine
- Drug Discovery/Drug Discovery Support
